A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval

NCT03577275 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias

Interventions

DRUG: NST-4016 600mg
DRUG: Placebo oral capsule
DRUG: Moxifloxacin 400mg
DRUG: NST-4016 2000mg

Sponsor

NorthSea Therapeutics B.V.